Loading…
Loading…
SOLV does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for SOLV and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SOLV and 80,000+ other tickers.
See exactly how SOLV's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SOLV and 80,000+ other tickers.
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical…
Solventum (SOLV) reported earnings 30 days ago. What's next for the stock?
EAGAN, Minn., Sept. 2, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, Sept.
Solventum's growth, higher earnings outlook and cost cuts strengthen its case, but heavy debt and 2027 margin risks temper the upside.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Shares of Solventum Corporation (NYSE: SOLV - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy